Syndax Announces Participation in June Investor Conferences
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative…
10,050€
4,69%
Echtzeit-Aktienkurs Syndax Pharmaceuticals
Bid:
Ask:
Nachrichten zur Syndax Pharmaceuticals Aktie
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2025 Earnings Call Transcript
…
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates
Syndax (SNDX) delivered earnings and revenue surprises of 5.77% and 36.69%, respectively, for the quarter ended March 2025. Do the…
Syndax Pharmaceuticals’ 41% decline validates InvestingPro’s bearish call By Investing.com
Syndax Pharmaceuticals’ 41% decline validates InvestingPro’s bearish call…
Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025
WALTHAM, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an…
Syndax Pharmaceuticals, Inc. (SNDX) Q3 2024 Earnings Call Transcript
…
Syndax Pharmaceuticals, Inc. 2024 Q3 - Results - Earnings Call Presentation
…
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2024 Earnings Call Transcript
…
Earnings call: Syndax Pharmaceuticals outlines robust Q1 2024 performance By Investing.com
Earnings call: Syndax Pharmaceuticals outlines robust Q1 2024 performance…
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2024 Earnings Call Transcript
…
Syndax (SNDX) Gets FDA Priority Tag for Leukemia Drug NDA
Syndax Pharmaceuticals (SNDX) groundbreaking menin inhibitor, revumenib, receives FDA priority review for treating relapsed, refractory acute leukemia.…
Earnings call: Syndax Pharmaceuticals eyes 2024 launches, discusses trials By Investing.com
Earnings call: Syndax Pharmaceuticals eyes 2024 launches, discusses trials…
Syndax Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation
…
Syndax Pharmaceuticals, Inc. (SNDX) Q4 2023 Earnings Call Transcript
…